These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 20694749)
1. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Cavallone L; Arcand SL; Maugard CM; Nolet S; Gaboury LA; Mes-Masson AM; Ghadirian P; Provencher D; Tonin PN Fam Cancer; 2010 Dec; 9(4):507-17. PubMed ID: 20694749 [TBL] [Abstract][Full Text] [Related]
2. The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Cote S; Arcand SL; Royer R; Nolet S; Mes-Masson AM; Ghadirian P; Foulkes WD; Tischkowitz M; Narod SA; Provencher D; Tonin PN Breast Cancer Res Treat; 2012 Jan; 131(1):333-40. PubMed ID: 21947752 [TBL] [Abstract][Full Text] [Related]
3. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Tonin PN Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226 [TBL] [Abstract][Full Text] [Related]
4. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Arcand SL; Maugard CM; Ghadirian P; Robidoux A; Perret C; Zhang P; Fafard E; Mes-Masson AM; Foulkes WD; Provencher D; Narod SA; Tonin PN Breast Cancer Res Treat; 2008 Apr; 108(3):399-408. PubMed ID: 17541742 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680 [TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152 [TBL] [Abstract][Full Text] [Related]
8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
9. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Tonin PN; Mes-Masson AM; Futreal PA; Morgan K; Mahon M; Foulkes WD; Cole DE; Provencher D; Ghadirian P; Narod SA Am J Hum Genet; 1998 Nov; 63(5):1341-51. PubMed ID: 9792861 [TBL] [Abstract][Full Text] [Related]
10. Germline TP53 mutational spectrum in French Canadians with breast cancer. Arcand SL; Akbari MR; Mes-Masson AM; Provencher D; Foulkes WD; Narod SA; Tonin PN BMC Med Genet; 2015 Apr; 16():24. PubMed ID: 25925845 [TBL] [Abstract][Full Text] [Related]
11. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Tonin PN; Perret C; Lambert JA; Paradis AJ; Kantemiroff T; Benoît MH; Martin G; Foulkes WD; Ghadirian P Int J Cancer; 2001 May; 95(3):189-93. PubMed ID: 11307153 [TBL] [Abstract][Full Text] [Related]
12. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. Ricks-Santi L; McDonald JT; Gold B; Dean M; Thompson N; Abbas M; Wilson B; Kanaan Y; Naab TJ; Dunston G Ethn Dis; 2017; 27(2):169-178. PubMed ID: 28439188 [TBL] [Abstract][Full Text] [Related]
13. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age. Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450 [TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. Buffone A; Capalbo C; Ricevuto E; Sidoni T; Ottini L; Falchetti M; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G Breast Cancer Res Treat; 2007 Dec; 106(2):289-96. PubMed ID: 17333342 [TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia. Jakimovska M; Maleva Kostovska I; Popovska-Jankovic K; Kubelka-Sabit K; Karadjozov M; Stojanovska L; Arsovski A; Smichkoska S; Lazarova E; Jakimovska Dimitrovska M; Plaseska-Karanfilska D Breast Cancer Res Treat; 2018 Apr; 168(3):745-753. PubMed ID: 29335924 [TBL] [Abstract][Full Text] [Related]
17. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing. Riahi A; Chabouni-Bouhamed H; Kharrat M Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807 [TBL] [Abstract][Full Text] [Related]
20. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]